Developing comprehensive screening for early-stage cancer is the key to saving the most lives.
Although multi-cancer early detection (MCED) tests are still being researched and lack FDA approval, several are commercially available for consumers who are willing to pay out of pocket. Individuals can ask their doctor to order the Galleri blood test from Grail, or they can opt for a whole-body MRI from companies like Prenuvo or Ezra, which often costs $2,000 or more.
Soon, consumers will have another — and rather unique—way to screen for multiple types of cancer.
SpotitEarly, a biotech company that’s part of Startup Battlefield at TechCrunch Disrupt 2025, is developing an at-h
Continue Reading on TechCrunch
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.